Rare diseases
Investigational molecules
Locations
Study Comparing Chemotherapy with Nivolumab to Chemotherapy Alone for Patients with Resectable Non-small Cell Lung Cancer
BelgiumStudy on SOT102 for Patients with Advanced Gastric and Pancreatic Cancer, Alone or with Drug Combination
BelgiumStudy of Nivolumab, Ipilimumab, or Cabazitaxel for Men with Advanced Prostate Cancer Resistant to Hormone Therapy
GermanyStudy of Relatlimab and Nivolumab for Children and Young Adults with Recurrent or Refractory Hodgkin and Non-Hodgkin Lymphoma
FranceStudy Comparing Nivolumab and Ipilimumab with Sunitinib for Patients with Advanced or Metastatic Kidney Cancer
AustriaStudy on the Safety and Effects of Nivolumab, Ipilimumab, Gemcitabine, and Paclitaxel for Patients with Advanced Pancreatic Cancer
DenmarkStudy on the Effectiveness of Ipilimumab and Nivolumab for Patients with Bladder Cancer
The NetherlandsStudy of Nivolumab with Chemotherapy for Children and Teenagers with Refractory or Relapsing Solid Tumors or Lymphoma
FranceStudy on Mitomycin, Capecitabine, Ipilimumab, and Nivolumab for Muscle Invasive Bladder Cancer Treatment in Patients Seeking Bladder-Sparing Options
The NetherlandsStudy on Cabozantinib, Nivolumab, and Ipilimumab for Patients with Advanced or Metastatic Kidney Cancer Who Have Not Received Prior Treatment
BelgiumStudy Comparing Tivozanib and Nivolumab Combination to Tivozanib Alone in Patients with Renal Cell Carcinoma After Previous Immune Therapy
BelgiumStudy on the Effectiveness of Nivolumab, Ipilimumab, and Pazopanib in Patients with Advanced Rare Sarcomas
FranceTell us about your condition – we search every trial in Europe and connect you with the right site.
